Zai Lab Limited (ZLAB) Q3 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary and Q&A indicate strong product development and strategic business updates, particularly in the pipeline and market expansion. Despite some challenges, such as supply constraints and competitive pressures, the company maintains a positive outlook with reaffirmed revenue guidance and expected profitability. The focus on AI, operational efficiency, and shareholder returns further supports a positive sentiment. Given the small-cap status, the stock is likely to react positively, but not overly so, hence a 'Positive' rating.
Key Financial Performance
Total Revenue $116.1 million, representing 14% growth year-over-year. Growth was primarily driven by higher sales of NUZYRA supported by increasing market coverage and penetration. However, ZEJULA declined year-over-year due to evolving competitive dynamics within the PARP class.
VYVGART and VYVGART Hytrulo Revenue $27.7 million, which includes a $2.4 million reduction following a voluntary price adjustment on Hytrulo to align with NRDL guidelines ahead of national pricing negotiations. Despite the adjustment, VYVGART remains a top innovative drug by sales among new launches in the past 2 years.
R&D Expenses Decreased 27% year-over-year, mainly due to a decrease in licensing fees in connection with upfront and milestone payments.
SG&A Expenses Increased 4% year-over-year, mainly due to higher general selling expenses to support the growth of NUZYRA and VYVGART, partially offset by lower selling expenses for ZEJULA.
Loss from Operations Improved 28% year-over-year to $48.8 million. Adjusted loss from operations was $28 million, a 42% improvement from the prior year, driven by financial discipline and efficiency.
Cash Position $817 million at the end of the quarter, providing flexibility to invest in innovation and disciplined execution.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Zoci (ZL-1310): Entered pivotal stage within 2 years from Phase 1/1b. Demonstrated strong efficacy in small cell lung cancer with a 68% overall response rate and 94% disease control rate. Phase III trial enrollment has begun.
ZL-1503: Entered Phase I for atopic dermatitis. Targets itch and inflammation with potential for less frequent dosing.
ZL-6201: On track for U.S. IND submission and global Phase I study initiation for cancer.
ZL-1222: Undergoing IND-enabling work for PD-1 IL-12 immunocytokine.
VYVGART: Achieved $27.7 million in revenue, ranking as the #1 innovative drug by sales among new launches in China over the past 2 years. Penetration in gMG is 12%, with significant room for growth.
KarXT: Under regulatory review for schizophrenia in China. Included in the 2025 China Schizophrenia Prevention and Treatment Guidelines.
Revenue Growth: Total revenue grew 14% year-over-year to $116.1 million, driven by NUZYRA and VYVGART sales.
Cost Efficiency: R&D expenses decreased by 27% year-over-year, and SG&A expenses increased by only 4%.
Global Pipeline Expansion: Focus on advancing innovative assets like Zoci and ZL-1503, with plans for multiple registrational studies and first-in-human data in 2026.
China Market Strategy: Emphasis on shaping the market for VYVGART and preparing for KarXT launch to redefine schizophrenia treatment.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Slower-than-expected commercial growth in China: The pace of commercial growth in China has been slower than anticipated, attributed to a complex and dynamic environment. This could impact revenue growth and long-term profitability.
Competitive dynamics in the PARP class: ZEJULA sales declined year-over-year due to evolving competitive dynamics within the PARP inhibitor class, posing a challenge to maintaining market share.
Supply chain normalization for XACDURO: Demand for XACDURO remains robust, but supply normalization is only expected by year-end, which could temporarily impact sales and customer satisfaction.
Regulatory and pricing pressures: A voluntary price adjustment for VYVGART Hytrulo to align with NRDL guidelines affected reported sales, highlighting the impact of regulatory and pricing pressures on revenue.
Market development challenges for VYVGART: The market build for VYVGART in gMG has been slower than expected, requiring significant physician education and changes in long-standing treatment patterns, which could delay revenue realization.
Dependence on pipeline milestones: The company’s future growth heavily depends on achieving key milestones in its pipeline, such as Zoci’s Phase III trials and other registrational studies. Delays or failures in these milestones could adversely impact strategic objectives.
Economic uncertainties: Broader economic uncertainties could affect healthcare spending and market dynamics, potentially impacting the company’s financial performance.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Zoci (ZL-1310): Expected first global approval by 2027 or early 2028. Registrational Phase III trial in extensive stage small cell lung cancer has begun enrollment, with potential for accelerated approval submission. Plans to initiate a Phase III study in first-line small cell lung cancer next year. Studies with novel combinations across lines of therapy are planned. Results in neuroendocrine carcinoma expected in the first half of next year, with plans to move into a registrational study thereafter.
ZL-1503 (IL-13/IL-31 bispecific antibody): Recently entered Phase I for atopic dermatitis. First-in-human data expected in 2026. Preclinical results support its use in other inflammatory diseases.
ZL-6201 (LRRC15 targeted antibody): On track for a U.S. IND submission by year-end and a global Phase I study initiation early next year for patients with cancer.
ZL-1222 (PD-1 IL-12 immunocytokine): IND-enabling work is underway, with plans to move quickly towards an IND once data are available.
Efgartigimod: Three additional Phase III readouts in Ocular myasthenia gravis, Myositis, and Thyroid eye disease expected next year. China contributing to global enrollment.
Povetacicept: FDA breakthrough therapy designation for IgAN received. Interim analysis for the global RAINIER Phase 3 planned for the first half of 2026, potentially supporting an accelerated approval submission next year. Global pivotal Phase II/III study in primary membranous nephropathy initiated in October, with plans to enroll patients in China this quarter.
VYVGART: Expected durable long-term growth in gMG market with significant room for expansion. Updated MG guidelines emphasize a minimum of 3 treatment cycles, supporting a shift from episodic to maintenance use. Volumes have grown sequentially in the mid-teens, with sustainable growth expected into 2026.
KarXT: Currently under regulatory review. Potential to redefine schizophrenia treatment in China as the first new mechanism of action in over 70 years. Already included in the China Schizophrenia Prevention and Treatment Guidelines 2025 Edition.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:On the revised revenue guidance, what are the key drivers for growth and the path to profitability?
A:Key drivers for growth include VYVGART, which is expected to see sequential growth driven by new patient additions and durability in doses. ZEJULA is expected to return to growth despite choppy quarterly numbers due to generic entries for Lynparza. XACDURO shows progress but faces supply constraints. Profitability will be driven by growth in the China business, which is already profitable and expected to cover R&D and corporate costs as top-line growth continues.
Q:Can you set expectations for the initial data readout for ZL-1503 expected in 2026 and discuss the opportunity in atopic dermatitis?
A:ZL-1503 is a dual IL-13/31 inhibitor with a long half-life, expected to show fast and sustained effects. Initial data from a placebo-controlled trial will be available by mid-2026. The opportunity in atopic dermatitis is significant, with potential expansion into other TH2 diseases like asthma and rhinitis.
Q:Is there a shift in resource allocation from external BD to the internal pipeline?
A:The company is prioritizing investment in its global pipeline, including advancing 1310 and expanding into neuroendocrine tumors. While internal programs are a focus, the company will continue to pursue targeted external opportunities on a global and regional basis.
Q:Where is the greatest opportunity and likelihood for success in the internal global pipeline among LRRC, PD-1, IL-2, and others?
A:The most immediate opportunity is 1310, which is active and well-tolerated with strong effects on brain metastases. LRRC15 is promising for targeting tumors via fibroblasts in the tumor microenvironment. PD-1 IL-12 has been engineered to reduce toxicity and shows potential in restoring PD-1 resistant tumors. Two INDs are expected this year, with PD-1 IL-12 entering trials next year.
Q:What is being done to set up for a strong KarXT launch, and what has been learned about the schizophrenia market in China?
A:KarXT is expected to launch with a targeted sales force in China, focusing on large institutions. The schizophrenia market in China presents a significant opportunity due to the lack of new mechanisms in 70 years. Approval is anticipated in 2026, with NRDL listing in 2027.
Q:What are the updated views on the $2 billion revenue target by 2028, and what is the pathway to approval for ZL1310 in neuroendocrine tumors?
A:The company remains optimistic about the $2 billion target, with contributions from sales outside China, including potential U.S. approval of 1310 in 2027. For neuroendocrine tumors, the pathway involves single-arm trials or physician choice comparators, with a focus on response rates above 30%-40%.
Q:What challenges have been encountered in the China environment for VYVGART and ZEJULA, and is the fourth-quarter cash breakeven target still intact?
A:Challenges include slower-than-expected ramp-up for VYVGART and delays in ZEJULA gaining share due to Lynparza generics. Fourth-quarter cash breakeven is unlikely, but progress toward profitability continues.
Q:What is the strategy for the early-stage pipeline buildup, particularly in oncology and immunology?
A:The strategy includes focusing on antibody drug conjugates, immunocytokines, and T cell engagers in oncology. In immunology, the focus is on cytokines, bispecifics, and signal transduction pathways. The company remains opportunistic for novel mechanisms with differentiation and significant patient impact.
Q:What visibility or leading indicators exist for VYVGART sales in Q4 and 2026, and what is the path forward for Bema in China?
A:VYVGART sales are expected to grow sequentially in the low teens, with progress toward an average of 3 cycles per year. For Bema, approval in China is unlikely due to challenges with the data set, and resources will be redirected to other pipeline opportunities.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on the revised $2 billion revenue target by 2028, stating they would provide a more comprehensive update next year. Additionally, they did not offer clear guidance on the fourth-quarter cash breakeven target, only indicating progress toward profitability.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Hytrulo
III study
III trial
IND
LRRC
PD
Phase III
VYVGART gMG
ZL IL
adjustment
approval submission
bispecific
brain metastasis
cancer study
catalyst
chapter
combination study
demand
differentiation
disease control
dos line
expansion
guideline
industry
line cell
mechanism action
milligram kilogram
negotiation
pace
patient China
patient date
quality
review
sign
speed
symptom control
treatment duration
use
vision
ZLAB Transcript
Zai Lab Limited (ZLAB) Q1 2026 Earnings Call Transcript
Unknown5-7
The earnings call lacked detailed discussions on critical topics like operational updates and strategic initiatives. The emphasis on forward-looking risks without concrete financial figures, especially regarding adjusted loss from operations, suggests uncertainty. This lack of clarity and potential risk exposure could lead to a negative market reaction.
Zai Lab Limited (ZLAB) Q4 2025 Earnings Call Transcript
Positive2-26
The earnings call summary and Q&A indicate strong product development, strategic market positioning, and potential for growth, especially with new launches like KarXT and expansion of VYVGART. The company shows disciplined financial management and a focus on profitability. However, some uncertainties in full-year guidance and market dynamics temper the outlook slightly. Overall, the sentiment leans positive with potential for stock appreciation.
Zai Lab Limited (ZLAB) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Neutral1-13
Zai Lab Limited (ZLAB) Q3 2025 Earnings Call Transcript
Positive11-7
The earnings call summary and Q&A indicate strong product development and strategic business updates, particularly in the pipeline and market expansion. Despite some challenges, such as supply constraints and competitive pressures, the company maintains a positive outlook with reaffirmed revenue guidance and expected profitability. The focus on AI, operational efficiency, and shareholder returns further supports a positive sentiment. Given the small-cap status, the stock is likely to react positively, but not overly so, hence a 'Positive' rating.
ZLAB Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
